Molbio Diagnostics’ management addressed key investor questions in an IPOScan interview, covering the company’s business model, market share, plans to reduce debt following listing, and the proportion of revenue driven by TB diagnostic kits. The discussion highlighted the diagnostics major’s financial priorities and growth trajectory as a newly listed public company.